<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162382</url>
  </required_header>
  <id_info>
    <org_study_id>WUSM3621222-201110079</org_study_id>
    <nct_id>NCT01162382</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Magnetic Stimulation for Treating Depression: A Functional Magnetic Resonance Imaging Study</brief_title>
  <official_title>Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder: A Functional Connectivity Magnetic Resonance Imaging (fcMRI) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol, &quot;Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of
      Major Depressive Disorder (MDD): A Functional Connectivity Magnetic Resonance Imaging (fcMRI)
      Study,&quot; is an open-label pilot treatment study. The purpose of the present protocol is to
      treat participants with a diagnosis of Major Depressive Disorder with 4 weeks of rTMS,
      performing fcMRI and EEG studies prior to and following treatment to determine if treatment
      response is related to changes in fcMRI and/or EEG results. The investigators hypothesize
      that patients who respond to treatment will display changes in functional connectivity
      patterns thought to be related to the occurrence of depressive symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is accompanied by rumination that supports inwardly focused cognitive attention on
      negative events and emotions. There is evidence to indicate that one aspect of this
      ruminative behavior lies in an abnormal increase in intra-regional connectivity among
      elements of the default mode network (DMN). It is also widely recognized that depression is
      associated with disturbances of cognition that include deficits in attentional processing,
      including both reductions in processing speed and deficits in selective attentional
      processing that are considered a part of executive function. Thus, there is at least equal
      reason to believe that attention and executive control networks might show changes in
      intra-regional functional connectivity. Given the attentional deficits associated with MDD,
      we hypothesize that there will be a weakening of intra-network resting state BOLD functional
      connectivity (rs-fcMRI) in addition to the strengthened connectivity reported by
      others.Further, we suggest that these shifts in intra-regional connectivity extend to the
      well-recognized anti-correlated activity between these two networks and support the intrusion
      of introspective, ruminative thought on cognitive activities that require externally directed
      attention. To test this hypothesis, we will use fMRI resting state functional connectivity to
      examine shifts in network connectivity prior to and following rTMS treatment for depression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Grant support ended following which the key personnel (PI) left the institution.
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale-24 Point Version (HDRS-24)</measure>
    <time_frame>At study entry and within 2 days of exiting 4 weeks of rTMS treatment</time_frame>
    <description>HDRS-24 will be used to measure response to rTMS treatment. A 50% decrease in HDRS-24 score will indicate treatment response; HDRS-24 &lt; 10 will indicate remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fCMRI Results</measure>
    <time_frame>At study entry and within 2 days of exiting 4 weeks of rTMS treatment</time_frame>
    <description>Imaging studies will be compared to determine if any changes in functional connectivity can be correlated with treatment response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Transcranial Magnetic Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label transcranial magnetic stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation</intervention_name>
    <description>Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.</description>
    <arm_group_label>Transcranial Magnetic Stimulation</arm_group_label>
    <other_name>Magstim Rapid stimulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        SCREENING/DIAGNOSTIC REQUIREMENTS:

          -  Male or female outpatients, ages 18-50 (some literature has shown increasing cortical
             distance with age that may affect treatment outcome

          -  Hamilton Rating Scale of Depression (HRSD-24) &gt; 18

          -  New onset major depression or untreated recurrent major depression per DSM-IV-TR38
             criteria.

          -  Not taking antidepressant medication or any other psychotropic medication

          -  Using an adequate contraceptive method

          -  Able to give informed consent

          -  Available for 4 weeks of daily therapy, working hours, Mon.-Fri.

          -  English-speaking

        Exclusion Criteria:

        DIAGNOSTIC EXCLUSIONS:

          -  Co-morbid psychiatric diagnosis of bipolar disorder, acute OCD, schizophrenia or
             schizoaffective or concurrent treatment with outpatient ECT, or personality disorder
             or MDD with suicidal ideation as determined by history and/or by P.I. examination
             requiring hospital admission or referral for acute care.

          -  Previous failure to respond to treatment with rTMS

          -  Failure to achieve satisfactory improvement in depression after two or more adequate
             trials of antidepressant medications.

        MEDICAL EXCLUSIONS:

          -  Patients newly diagnosed with thyroid dysfunction

          -  History of drug and/or ETOH dependence

          -  History of seizures

          -  History of head injury with loss of consciousness &gt; 5 minutes

          -  Any implantable metal object in the skull or near their head

          -  Any implantable devices such as a cardiac pacemaker, vagal nerve stimulator, etc.

          -  Positive urine pregnancy test

          -  Severe migraine headaches uncontrolled with routine non-narcotic medication

          -  Any medical condition in the opinion of the Investigator that might confound the
             results of the study Contraindications to fcMRI procedure

          -  Intake of NSAIDS, narcotic or muscle relaxants within 72 hours of the fMRI protocol.

          -  Claustrophobia.

          -  Left-handedness (may influence cerebral cortical hemispheric dominance).

          -  Inability to tolerate, or medical contraindication to MRI testing (e.g. metal
             prostheses or implants, history of claustrophobia)

        PROTOCOL SPECIFIC EXCLUSIONS:

          -  Unable to determine motor threshold for determining treatment dose with rTMS device

          -  Mini Mental Status Exam (MMSE)70 score &lt; 24.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull. 2009;42(2):5-38. Review.</citation>
    <PMID>19629020</PMID>
  </reference>
  <reference>
    <citation>Broyd SJ, Demanuele C, Debener S, Helps SK, James CJ, Sonuga-Barke EJ. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev. 2009 Mar;33(3):279-96. doi: 10.1016/j.neubiorev.2008.09.002. Epub 2008 Sep 9. Review.</citation>
    <PMID>18824195</PMID>
  </reference>
  <reference>
    <citation>O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007 Dec 1;62(11):1208-16. Epub 2007 Jun 14.</citation>
    <PMID>17573044</PMID>
  </reference>
  <reference>
    <citation>Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience. 2009 Nov 24;164(1):300-30. doi: 10.1016/j.neuroscience.2009.03.082. Epub 2009 Apr 7. Review.</citation>
    <PMID>19358877</PMID>
  </reference>
  <reference>
    <citation>Zou K, Deng W, Li T, Zhang B, Jiang L, Huang C, Sun X, Sun X. Changes of brain morphometry in first-episode, drug-na√Øve, non-late-life adult patients with major depression: an optimized voxel-based morphometry study. Biol Psychiatry. 2010 Jan 15;67(2):186-8. doi: 10.1016/j.biopsych.2009.09.014.</citation>
    <PMID>19897176</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <results_first_submitted>February 8, 2019</results_first_submitted>
  <results_first_submitted_qc>February 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2019</results_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transcranial magnetic stimulation</keyword>
  <keyword>TMS</keyword>
  <keyword>rTMS</keyword>
  <keyword>depression</keyword>
  <keyword>fcMRI</keyword>
  <keyword>EEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transcranial Magnetic Stimulation</title>
          <description>Open-label transcranial magnetic stimulation
Transcranial Magnetic Stimulation: Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No data are available for this study as the study was terminated and PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed.</population>
      <group_list>
        <group group_id="B1">
          <title>Transcranial Magnetic Stimulation</title>
          <description>Open-label transcranial magnetic stimulation
Transcranial Magnetic Stimulation: Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale-24 Point Version (HDRS-24)</title>
        <description>HDRS-24 will be used to measure response to rTMS treatment. A 50% decrease in HDRS-24 score will indicate treatment response; HDRS-24 &lt; 10 will indicate remission.</description>
        <time_frame>At study entry and within 2 days of exiting 4 weeks of rTMS treatment</time_frame>
        <population>No data are available for this study as the study was terminated and PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Magnetic Stimulation</title>
            <description>Open-label transcranial magnetic stimulation
Transcranial Magnetic Stimulation: Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale-24 Point Version (HDRS-24)</title>
          <description>HDRS-24 will be used to measure response to rTMS treatment. A 50% decrease in HDRS-24 score will indicate treatment response; HDRS-24 &lt; 10 will indicate remission.</description>
          <population>No data are available for this study as the study was terminated and PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>fCMRI Results</title>
        <description>Imaging studies will be compared to determine if any changes in functional connectivity can be correlated with treatment response.</description>
        <time_frame>At study entry and within 2 days of exiting 4 weeks of rTMS treatment</time_frame>
        <population>No data are available for this study as the study was terminated and PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed.</population>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Magnetic Stimulation</title>
            <description>Open-label transcranial magnetic stimulation
Transcranial Magnetic Stimulation: Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.</description>
          </group>
        </group_list>
        <measure>
          <title>fCMRI Results</title>
          <description>Imaging studies will be compared to determine if any changes in functional connectivity can be correlated with treatment response.</description>
          <population>No data are available for this study as the study was terminated and PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No data are available for this study as the study was terminated and PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed.</time_frame>
      <desc>No data are available for this study as the study was terminated and PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Transcranial Magnetic Stimulation</title>
          <description>Open-label transcranial magnetic stimulation
Transcranial Magnetic Stimulation: Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No data are available for this study as the study was terminated and PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathy Pierce</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-5626</phone>
      <email>jenkerson_m@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

